Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of MELT-300 for Sedation and Analgesia in Cataract Surgery
NCT05133518Phase 2Completed
- Sponsor
- Melt Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of midazolam + ketamine in cataract, sponsored by Melt Pharmaceuticals. Started Jul 2021; status: completed.
02
Drugs
midazolam + ketamine
03
Conditions
cataract
Beyond the preview
Go deeper on NCT05133518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133518.